Novartis Pharmaceuticals Canada Inc. becomes a new partner of CQDM

Novartis Pharmaceuticals Canada Inc. becomes a new partner of CQDM 
$300,000 investment supports highly innovative research on drug discovery 
DORVAL, QC, Dec. 4, 2012 /CNW/ - Novartis Pharmaceuticals Canada Inc. has 
become the latest pharmaceutical company to partner in the innovative Explore 
program of the CQDM, with an investment of $300,000. Novartis is a significant 
contributor to Research & Development (R&D) in Quebec and has invested 
approximately 30% of its total sales in the province over the last 5 years. 
The Explore program is an initiative launched in 2010 by the CQDM as way of 
funding unconventional and highly innovative research projects that could 
impact the drug discovery process. Projects funded by this program must have 
the potential for a breakthrough discovery that could lead to an important 
change in the current paradigm or conventional wisdom. 
"Novartis is very pleased to be joining the CQDM and its other pharmaceutical 
industry partners in this very important program to encourage cutting-edge 
pharmaceutical research in Quebec," said Dr. Riad Sherif B., President of 
Novartis Pharmaceuticals Canada Inc. "The Explore program is fully compatible 
with the Novartis objectives to discover, develop and successfully market 
innovative products to prevent and cure disease, to ease suffering and to 
enhance quality of life." 
Globally, the biopharmaceutical research model is rapidly evolving to become 
more efficient and to optimize resources in the very expensive and risky 
endeavor of drug development. Increasingly, research activity is being 
conducted as collaborations with companies, research institutions and 
governments. The CQDM is a public-private partnership created four years ago 
as a new means to express Quebec's leadership in biopharmaceutical research 
and now counts seven pharmaceutical company partners. 
"We are very pleased to welcome Novartis as a partner in our Explore program 
to help ensure its ongoing success," said Diane Gosselin, President and CEO of 
CQDM. "This has rapidly become an important means for Quebec researchers with 
new ideas to secure funding to pursue their innovative approaches. Not every 
idea will succeed, however we need programs like Explore to uncover those 
promising ideas and to find new innovative approaches to managing disease." 
About the CQDM Explore Program
The Explore Program of the CQDM is a funding initiative for breakthrough 
technologies that have the potential to significantly improve the drug 
discovery or development process. It is aimed at supporting "smaller" projects 
that may carry more than the usual degree of scientific risk, and reinforce 
the commitment of the CQDM and its pharmaceutical company members to funding 
disruptive research. The Explore Program is dedicated to early-concept 
validation and technical feasibility of creative or innovative ideas that when 
fully developed may address some of the most important bottlenecks faced by 
the pharmaceutical industry in the drug R&D process. 
The Explore Program is open to the research community in Quebec from both 
public and private research institutions. Following an annual call for 
proposals, selected projects are eligible for up to $150,000 per year per 
project for two years. Each winning project is also assigned at least one 
mentor from the CQDM pharma members to ensure the commercial viability of 
projects and that they are aligned with industry needs. The three winning 2012 
projects were announced in September. 
About CQDM
CQDM is a meeting ground for all stakeholders in biopharmaceutical research. 
Its principal mission is to fund research projects carried out in partnership 
between the academic and private sectors. An innovative Canadian initiative, 
CQDM has a two-fold goal: to accelerate the drug discovery process and to 
develop safer and more effective drugs. CQDM is funded through contributions 
from Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., 
GlaxoSmithKline Inc., Eli Lilly Canada Inc., Novartis Pharmaceutical Canada 
Inc., the Business-Led Networks of Centres of Excellence (BL-NCE) and the 
Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de 
la Technologie du Québec. For more information: 
About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is 
committed to the discovery, development and marketing of innovative products 
to improve the well-being of all Canadians. In 2011, the company invested 
close to $100 million in research and development in Canada. Novartis 
Pharmaceuticals Canada Inc. employs more than 600 people in Canada. It was 
named for the seventh time as one of the "50 Best Employers in Canada" for 
2011. For further information, please consult 
Andrea Gilpin, Ph.D, MBA Director, Corporate Communications Novartis 
Pharmaceuticals Canada Inc. 514 631-6775 ext. 3356 
SOURCE: Novartis Pharmaceuticals Canada Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Novartis Pharmaceuticals Canada Inc.
ST: Quebec
-0- Dec/04/2012 19:31 GMT
Press spacebar to pause and continue. Press esc to stop.